New artificial disc could replace fusion for neck pain sufferers
NCT ID NCT03123549
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new artificial disc called the Simplify Disc for people with two-level cervical disc disease causing arm pain, neck pain, or nerve problems. The trial involved 182 participants and compared the disc to standard fusion surgery. The goal was to see if the disc is at least as safe and effective at reducing disability and improving neurological function over 24 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Simplify Cervical Artificial Disc (device)
- What this could lead to
- If successful, this artificial disc could offer a motion-preserving alternative to fusion surgery for people with two-level cervical disc disease, potentially reducing pain and disability while maintaining neck movement.
- What could go wrong
- This is a completed study comparing a device to standard surgery, but results may not apply to all patients. There are risks of implant failure, additional surgery, or serious adverse events.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
182 people
The number who actually took part.
- Started
-
Apr 2017
- Finished
-
Mar 2022
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Has cervical degenerative disc disease at two (2) adjacent cervical levels (from C3 C7) requiring surgical treatment and involving intractable radiculopathy, myelopathy, or both; * Has a herniated disc and/or osteophyte formation at each level to be treated that is producing symptomatic nerve root and/or spinal cord compression. The condition is documented by patient history (e.g., neck pain with arm pain, functional deficit and/or neurological deficit), and the requirement for surgical treatment is evidenced by radiographic studies (e.g., CT, MRI, x-rays, etc.); * Has been unresponsive to non-operative treatment for at least six weeks or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management; * Has no previous surgical intervention at the involved levels or any subsequent planned/staged surgical procedure at the involved or adjacent level(s); * Must be at least 18 years of age and be skeletally mature at the time of surgery; * Has a preoperative Neck Disability Index (NDI) ≥ 30; * Has a preoperative neck pain score \> 8 based on the preoperative Neck and Arm Pain Questionnaire; * If a female of childbearing potential, patient is non-pregnant, non-nursing, and agrees not to become pregnant during the study period; * Is willing to comply with the study plan and sign the Patient Informed Consent Form. Exclusion Criteria: * Has a cervical spinal condition other than symptomatic cervical DDD requiring surgical treatment at the involved levels; * Has documented or diagnosed cervical instability relative to adjacent segments at either level, defined by dynamic (flexion/extension) radiographs showing: * Sagittal plane translation \> 3.5 mm, or * Sagittal plane angulation \> 20°; * Has more than two cervical levels requiring surgical treatment; * Has a fused level (or artificial disc replacement) adjacent to the levels to be treated; * Has severe pathology of the facet joints of the involved vertebral bodies; * Has had previous surgical intervention at either one or both of the involved levels or at adjacent levels; * Axial neck pain only (no radicular or myelopathy symptoms); * Has been previously diagnosed with osteopenia or osteomalacia; * Has any of the following that may be associated with a diagnosis of osteoporosis (if "Yes" to any of the below risk factors, a DEXA Scan will be required to determine eligibility): * Postmenopausal non-black female over 60 years of age who weighs less than 140 pounds; * Postmenopausal female who has sustained a non-traumatic hip, spine, or wrist fracture; * Male over the age of 70; * Male over the age of 60 who has sustained a non-traumatic hip or spine fracture. * If the level of bone mineral density is a T score of -1.5 or lower (i.e., -1.6, 1.7, etc.), then the patient is excluded from the study * Has presence of spinal metastases; * Has overt or active bacterial infection, either local or systemic; * Has insulin-dependent diabetes; * Has chronic or acute renal failure or prior history of renal disease; * Known PEEK, ceramic, titanium allergy; * Is mentally incompetent (if questionable, obtain psychiatric consult); * Is a prisoner; * Is pregnant; * Is currently an alcohol and/or drug abuser or currently undergoing treatment for alcohol and/or drug abuse; * Is involved with current or pending litigation regarding a spinal condition; * Has received drugs that may interfere with bone metabolism within two weeks prior to the planned date of spinal surgery (e.g., steroids or methotrexate), excluding routine perioperative anti-inflammatory drugs; * Has a history of an endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's Disease, renal osteodystrophy, Ehlers-Danlos Syndrome, or osteogenesis imperfecta); * Has a condition that requires postoperative medications that interfere with the stability of the implant, such as steroids. (This does not include low-dose aspirin for prophylactic anticoagulation and routine perioperative anti-inflammatory drugs); * Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following implantation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical degenerative disc disease with radiculopathy or myelopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Buffalo Spine Surgery
Lockport, New York, 14094, United States
-
Carolina Neurosurgery and Spine Associates
Charlotte, North Carolina, 28204, United States
-
Connecticut Orthopaedic Specialists
Hamden, Connecticut, 06518, United States
-
Indiana Spine Group
Carmel, Indiana, 46032, United States
-
Kennedy-White orthopedic Center
Sarasota, Florida, 34232, United States
-
NorthShore University Health System
Evanston, Illinois, 60201, United States
-
Oregon Neurosurgery
Springfield, Oregon, 97477, United States
-
Orthopaedic Education and Research Institute of Southern California
Orange, California, 92868, United States
-
Orthopaedic Institute of Western Kentucky
Paducah, Kentucky, 42003, United States
-
Parkview Research Center
Fort Wayne, Indiana, 46845, United States
-
Spine Education and Research Foundation
Thornton, Colorado, 80229, United States
-
Spine institute of Louisiana
Shreveport, Louisiana, 71101, United States
-
Texas Back Institute
Plano, Texas, 75093, United States
-
Texas Spine Consultants
Addison, Texas, 75001, United States
-
The Disc Replacement Center
West Jordan, Utah, 84088, United States
-
The Spine Institute for Spine Restoration
Santa Monica, California, 90403, United States
-
Virginia Spine Institute
Reston, Virginia, 20191, United States
-
William Beaumont Hospital
Royal Oak, Michigan, 48073, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.